Subscribe to news

Press Releases

04.05.2012
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announces its unaudited results for the first quarter of 2012 in accordance with the Russian Accounting Standards (RAS).
28.04.2012
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announced the decision of the Company’s Board of Directors on convocation of the Annual General Shareholders’ Meeting upon the results of 2011.
12.03.2012
OJSC HSCI – The Human Stem Cells Institute ("HSCI", MICEX: ISKJ), one of Russia's leading biotech companies, has announced the results of the first two years following its IPO and presented an overview of the Company's strategy for 2012-2016.
07.12.2011
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), Russia’s biotech company, announced today that it has received state approval for Neovasculgen® – the first Russian gene-therapy drug to treat Peripheral Arterial Disease.
06.09.2011
OJSC HSCI – The Human Stem Cells Institute ("HSCI", MICEX:ISKJ), a Russian company engaged in the development, manufacturing and commercialization of products and services in the realm of cell-based, gene and post-genome technologies, announced today that its Extraordinary General Shareholders' Meeting has approved an Investment agreement for the SynBio project - the first ever international M&A in the global biotech sector initiated by a Russian company.
04.08.2011
OJSC HSCI – The Human Stem Cells Institute (MICEX: ISKJ), a Russian company engaged in the development, manufacturing and commercialization of products and services in the realm of cell-based, gene and post-genome technologies, today announces the parameters of the SynBio project.